ProShares UltraShort NASDAQ Biotechnology
6 hedge funds and large institutions have $1.26M invested in ProShares UltraShort NASDAQ Biotechnology in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0.04% more ownership
Funds ownership: 8.69% → 8.73% (+0.04%)
14% less funds holding
Funds holding: 7 → 6 (-1)
21% less capital invested
Capital invested by funds: $1.6M → $1.26M (-$340K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMC Chicago
Chicago,
Illinois
|
+$231K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$214K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$28K |
| 4 |
Morgan Stanley
New York
|
+$3.17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$556K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$229K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$20K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
IMC Chicago
Chicago,
Illinois
| $495K | +$231K | +6,628 | +93% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $388K | -$229K | -6,555 | -38% |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $317K | +$214K | +6,142 | +232% |
|
|
4
UBS Group
Zurich,
Switzerland
| $55K | +$28K | +803 | +113% |
|
|
5
Morgan Stanley
New York
| $3K | +$3.17K | +91 | New |
|
6
Citigroup
New York
| $2K | – | – | – |
|
|
OMC
7
Old Mission Capital
Chicago,
Illinois
| – | -$556K | -15,107 | Closed |
|
|
8
Osaic Holdings
Scottsdale,
Arizona
| – | -$20K | -549 | Closed |
|
BIS Hedge Fund Activity: Q3 2021 in Review
6 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q3 2021, worth a combined $1.26M — down 21% from $1.6M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BIS and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.
The largest buyer was IMC Chicago, adding an estimated $231K. The largest seller was Old Mission Capital, exiting entirely with an estimated $556K sold.
- 6 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q3 2021, down from 7 in Q2 2021.
- Funds reported $1.26M of ProShares UltraShort NASDAQ Biotechnology stock for Q3 2021, down 21% quarter-over-quarter.
- 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q3 2021 and 2 closed out, a net change of -1 holder.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q3 2021 was IMC Chicago, an estimated $231K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q3 2021 was Old Mission Capital, an estimated $556K sold.
Based on aggregated 13F filings for Q3 2021.